(810) Chenodal
Drug
Retrophin, Inc.
Total Payments
$2.3M
Transactions
1,035
Doctors
48
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $601,692 | 234 | 1 |
| 2019 | $748,814 | 201 | 6 |
| 2018 | $595,259 | 300 | 25 |
| 2017 | $383,880 | 300 | 23 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.9M | 949 | 80.9% |
| Grant | $339,414 | 3 | 14.6% |
| Consulting Fee | $87,705 | 30 | 3.8% |
| Travel and Lodging | $15,940 | 17 | 0.7% |
| Food and Beverage | $1,820 | 24 | 0.1% |
| Education | $648.95 | 12 | 0.0% |
Payments by Type
Research
$1.9M
949 transactions
General
$445,527
86 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| 018CTXX15001 | Retrophin, Inc. | $526,379 | 0 |
| Protocol No: 018CTXX15001 | Travere Therapeutics, Inc. | $525,682 | 0 |
| CTA Site Pmts-CTX Prevalence | Retrophin, Inc. | $148,838 | 0 |
| CTX Prevalence Study | Retrophin, Inc. | $145,593 | 0 |
| CTX Prevalence 018CTXX15001 | Retrophin, Inc. | $56,663 | 0 |
| A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | Travere Therapeutics, Inc. | $41,082 | 0 |
| Amend #1 -screen Druze for CTX | Retrophin, Inc. | $35,400 | 0 |
| Amend#1-screen Druze for CTX | Retrophin, Inc. | $35,400 | 0 |
| Protocol No: 018CTXX15001 | Retrophin, Inc. | $29,802 | 0 |
| CTX Prevalence: CTX Observational study in patients with early onset bilateral cateracts | Travere Therapeutics, Inc. | $27,112 | 0 |
| Investig Sponsr Stdy MedAff Chenodal | Retrophin, Inc. | $23,400 | 0 |
| SRA-14-100 CTX Pilot Study | Retrophin, Inc. | $21,560 | 0 |
| FORT Study | Retrophin, Inc. | $20,251 | 11 |
| PNC when CTX Treated with Chenodiol | Retrophin, Inc. | $18,070 | 0 |
| ICE CTX ISR | Retrophin, Inc. | $17,580 | 0 |
| Cheno-CTX301 | Retrophin, Inc. | $15,176 | 0 |
| Prevalence of Cerebrotendinous Xanthomatosis | Retrophin, Inc. | $14,799 | 1 |
| CTX Prevalence 018CTXX15045 | Retrophin, Inc. | $11,469 | 0 |
| CTX Prevalence 018CTXX15021 | Retrophin, Inc. | $10,750 | 0 |
| Central IRB-CTX Prev Study | Retrophin, Inc. | $10,708 | 0 |
Top Doctors Receiving Payments for (810) Chenodal
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Seattle, WA | $2.2M | 941 |
| , M.D | Endocrinology, Diabetes & Metabolism | Boston, MA | $27,262 | 5 |
| , MD | Clinical Biochemical Genetics | Madison, WI | $27,227 | 20 |
| Gerald Salen | — | Newark, NJ | $21,000 | 4 |
| , M.D | Neurology | Boston, MA | $9,570 | 2 |
| , M.D | Specialist | New York, NY | $7,710 | 5 |
| , MD, PHD | Neurology | Chicago, IL | $7,500 | 1 |
| , MD | Neurology | Portland, OR | $2,800 | 2 |
| , M.D | Neurology | Columbus, OH | $2,661 | 3 |
| , MD | Endocrinology, Diabetes & Metabolism | Portland, OR | $2,515 | 2 |
| Maria Escolar | Pediatrics | Chapel Hill, NC | $2,425 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Cincinnati, OH | $2,400 | 1 |
| , MD | Neurology | Chicago, IL | $2,326 | 1 |
| , MD | Rehabilitation Practitioner | Oakland, CA | $2,182 | 1 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Miami, FL | $2,166 | 1 |
| , MD | Neurology with Special Qualifications in Child Neurology | Miami, FL | $2,166 | 1 |
| , M.D | Neurodevelopmental Disabilities | Phoenix, AZ | $2,138 | 1 |
| , M.D | Ophthalmology | Farmington, CT | $2,000 | 1 |
| , M.D | Pediatrics | Atlanta, GA | $1,959 | 1 |
| , MD PHD | Neurology | Atlanta, GA | $1,919 | 1 |
| , M.D | Pediatrics | Chicago, IL | $1,807 | 1 |
| , M.D | Pediatrics | New Orleans, LA | $1,800 | 5 |
| , MD | Neurology | Philadelphia, PA | $1,500 | 1 |
| , M.D | Pediatric Gastroenterology | East Hanover, NJ | $962.20 | 1 |
| Marc Chevrier | — | Collegeville, PA | $699.13 | 2 |
Ad
Manufacturing Companies
- Retrophin, Inc. $1.7M
- Travere Therapeutics, Inc. $601,692
Product Information
- Type Drug
- Total Payments $2.3M
- Total Doctors 48
- Transactions 1,035
About (810) Chenodal
(810) Chenodal is a drug associated with $2.3M in payments to 48 healthcare providers, recorded across 1,035 transactions in the CMS Open Payments database. The primary manufacturer is Retrophin, Inc..
Payment data is available from 2017 to 2020. In 2020, $601,692 was paid across 234 transactions to 1 doctors.
The most common payment nature for (810) Chenodal is "Unspecified" ($1.9M, 80.9% of total).
(810) Chenodal is associated with 20 research studies, including "018CTXX15001" ($526,379).